The global demand for Meningococcal Vaccine Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Meningococcal vaccine helps prevent meningococcal disease. The meningococcal disease is caused by Neisseria meningitides bacteria. The vaccines contain antigens substances that boost the body's immune system and cause it to make antibodies, these antibodies then protect the body by attacking and killing the bacteria. The vaccine is given either by injection into a muscle or just under the skin. There are three types of meningococcal vaccines available: Polysaccharide vaccines, conjugate vaccines, and protein based vaccine.
Growing incidence of meningococcal meningitis isdriving the growth of market. Meningococcal disease is potentially fatal, observed worldwide with reportable condition in all states, but the highest burden of the disease is in the sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.Market is predicted to experience new waves in the growth owing to the COVID-19, an emerging an rapidly evolving situation.Scientist across the world are focused on discovering vaccine for coronavirus. Various clinical trials are executed to determine the results. Number of drugs and vaccine is identified as candidate to eradicate COVID-19. ChAdOx1 nCoV-19, vaccine against meningococcal disease is among the one. This vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response and has appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version and market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of meningococcal vaccine.
The entire meningococcal vaccine market has been sub-categorized into product, age group, and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Age Group
- Polysaccharide Vaccines
- Conjugate Vaccines
- Protein Based Vaccine
By Distribution Channel
- Adolescenst & Young Adults
- Institutional Sales
- Retail Sales
This section covers regional segmentation which accentuates on current and future demand for meningococcal vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Meningococcal Vaccine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the meningococcal vaccine market include GlaxoSmithKline Plc., Novartis International, Serum Institute of India Ltd, Sanofi SA, and Pfizer Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.